Last updated on May 2018

Radium-223 Dichloride Long-term Follow-up Program

Brief description of study

Patients will be followed up in this study after prior treatment with BAY 88-8223 / Radium-223 dichloride / Xofigo.

Detailed Study Description

This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials).

The primary objectives are to define the long term safety profile of radium-223 dichloride (for up to 7 years after the last dose of radium-223 dichloride); to assess the incidence of leukemia, myelodysplastic syndrome, aplastic anemia, and primary bone cancer or any other new primary malignancy; and, in subjects who receive cytotoxic chemotherapy, to assess the incidence of febrile neutropenia and hemorrhage during their chemotherapy treatment and for up to 6 months thereafter at a frequency based on local clinical practice.

Clinical Study Identifier: NCT02312960

Find a site near you

Start Over

Bayer Clinical Trials Contact

Obninsk, Russian Federation
  Connect »

Bayer Clinical Trials Contact

Freiburg im Breisgau, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.